Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapy
Concurrent management of IBD and cancer poses clinical challenges, particularly with the higher risk of GI AEs (25.7%) that is associated with active baseline IBD status and ICI use. These interactions may compromise treatment and survival. Further research is warranted to clarify the long-term impact of cancer therapies on IBD progression and outcomes.
Authors
- Maria Julia Moura Nascimento Santos (ORCID: https://orcid.org/0000-0001-5743-9290)
- Sharada Wali
- Sidra Naz (ORCID: https://orcid.org/0000-0001-6390-9658)
- Rohan Ahuja (ORCID: https://orcid.org/0000-0003-3806-7035)
- Emily Zhou (ORCID: https://orcid.org/0000-0002-9194-7042)
- Kevin Shi (ORCID: https://orcid.org/0000-0001-9734-0324)
- Ninoska N. Silva
- Varun Vemulapalli
- Jessica Philpott
- Aliyah Pabani (ORCID: https://orcid.org/0009-0006-7605-8497)
- Arjun Peddireddy (ORCID: https://orcid.org/0009-0009-1442-7789)
- Nina Quirk
- Kristin Junek
- Jasmine Haydel (ORCID: https://orcid.org/0009-0009-9837-7423)
- Kazi T. Haque
- Andrew Ming-Chung Lee
- Eric Lu
- Anusha S. Thomas
- Cristina Natha
- Andrew Sullivan
- Carolina Colli Cruz
- Pooja Prasad
- Kei Takigawa
Institutions
- Cleveland Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Baylor College of Medicine (US)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1097/meg.0000000000003124
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00